KMT2A and acute myeloid leukemia: Notably, while revumenib induces myeloid differentiation in MLL-r AML—contrasting with its pro-apoptotic effects in acute lymphoblastic leukemia (ALL)—intrinsic resistance persists in certain AML cell lines [128].